A first-in-class mAb, directed against a key immune checkpoint, PVR (CD155). NTX1088 demonstrated superior antitumor activity compared to approved and investigational Immune Checkpoint Inhibitors (ICIs) in pre-clinical models. NTX1088 has a favorable safety profile in non-human primates (NHP). An ongoing phase 1 clinical trial is evaluating NXT1088 as a mono-therapy and in combination with KEYTRUDA® (pembrolizumab).
This project is co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
Nectin Therapeutics is engaged in the development of a pipeline of first-in-class and best-in-class ADC therapies. Our candidates have demonstrated robust tumor regression in multiple in vivo models of solid and hematological malignancies. Our ADC programs are currently undergoing IND-enabling studies.
A best-in-class mAb, targeting CD112R (PVRIG), a novel immune inhibitory receptor. NTX2R13 demonstrated superior therapeutic potential with an initial clean safety profile in NHP. Along with their single agent activity, NTX1088 and NTX2R13 synergize with each other, and exhibit noticeable synergy with approved PD(L)1 blockers in various preclinical studies, raising the possibility for the development of combination immunotherapy.